The Treat FTD Fund
The Treat FTD Fund supports innovative early-stage clinical trials developing therapies for frontotemporal degeneration, emphasizing strong scientific rationale, biomarkers, and tailored trial designs.
Funder: The Association for Frontotemporal Degeneration
Due Dates: November 9, 2018 (Letter of Intent) | February 15, 2019 (Invited Full Proposal) | June 1, 2026 (Full Proposal)
Funding Amounts: Up to $2,500,000 over 1–3 years per project; milestone-based payments; co-funding encouraged.
Summary: Supports early-stage clinical trials to advance effective treatments for frontotemporal degeneration, emphasizing strong scientific rationale, biomarkers, and innovative trial designs.
Description
The Treat FTD Fund, jointly launched by The Association for Frontotemporal Degeneration (AFTD) and the Alzheimer’s Drug Discovery Foundation (ADDF), provides critical funding for early-stage clinical trials aimed at developing effective treatments for frontotemporal degeneration (FTD) disorders. The fund focuses on trials with robust scientific rationales for targeting FTD-relevant biological mechanisms, incorporation of biomarkers to assess target engagement and biological effects, and innovative trial designs tailored to rare disease populations. Both disease-modifying and symptomatic therapies are eligible, including experimental and repurposed drugs, gene therapies, antisense oligonucleotides, peptides, antibodies, and device-based interventions. Non-pharmacologic interventions are also considered. The program strongly encourages leveraging existing research networks and patient registries to maximize study impact.
